Elekta AB (EKTAY)
7.246
-0.01
(-0.12%)
USD |
OTCM |
May 08, 15:49
Elekta Enterprise Value: 3.110B for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 07, 2024 | 3.110B |
| May 06, 2024 | 3.115B |
| May 03, 2024 | 3.039B |
| May 02, 2024 | 3.022B |
| May 01, 2024 | 3.027B |
| April 30, 2024 | 3.092B |
| April 29, 2024 | 3.075B |
| April 26, 2024 | 2.957B |
| April 25, 2024 | 2.898B |
| April 24, 2024 | 2.982B |
| April 23, 2024 | 3.031B |
| April 22, 2024 | 2.987B |
| April 19, 2024 | 2.909B |
| April 18, 2024 | 2.926B |
| April 17, 2024 | 2.963B |
| April 16, 2024 | 3.001B |
| April 15, 2024 | 3.047B |
| April 12, 2024 | 3.020B |
| April 11, 2024 | 3.133B |
| April 10, 2024 | 3.165B |
| April 09, 2024 | 3.248B |
| April 08, 2024 | 3.325B |
| April 05, 2024 | 3.266B |
| April 04, 2024 | 3.295B |
| April 03, 2024 | 3.320B |
| Date | Value |
|---|---|
| April 02, 2024 | 3.265B |
| April 01, 2024 | 3.232B |
| March 28, 2024 | 3.207B |
| March 27, 2024 | 3.230B |
| March 26, 2024 | 3.228B |
| March 25, 2024 | 3.231B |
| March 22, 2024 | 3.215B |
| March 21, 2024 | 3.217B |
| March 20, 2024 | 3.201B |
| March 19, 2024 | 3.226B |
| March 18, 2024 | 3.207B |
| March 15, 2024 | 3.255B |
| March 14, 2024 | 3.209B |
| March 13, 2024 | 3.208B |
| March 12, 2024 | 3.215B |
| March 11, 2024 | 3.166B |
| March 08, 2024 | 3.178B |
| March 07, 2024 | 3.219B |
| March 06, 2024 | 3.139B |
| March 05, 2024 | 3.060B |
| March 04, 2024 | 3.138B |
| March 01, 2024 | 3.211B |
| February 29, 2024 | 3.081B |
| February 28, 2024 | 3.043B |
| February 27, 2024 | 3.019B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.046B
Minimum
Sep 27 2022
6.004B
Maximum
Jun 07 2021
4.041B
Average
3.785B
Median
Jun 10 2020
Enterprise Value Benchmarks
| Abliva AB | 7.716M |
| Karolinska Development AB | 62.17M |
| Calliditas Therapeutics AB | 550.50M |
| Oncopeptides AB | 12.46M |
| Olink Holding AB | 2.766B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 29.37M |
| Revenue (Quarterly) | 436.89M |
| Total Expenses (Quarterly) | 382.20M |
| EPS Diluted (Quarterly) | 0.077 |
| Gross Profit Margin (Quarterly) | 36.68% |
| Profit Margin (Quarterly) | 6.72% |
| Earnings Yield | 4.90% |
| Operating Earnings Yield | 8.45% |
| Normalized Earnings Yield | 4.901 |